Supplemental Material for

Chemokine Receptor 2 Is A Theranostic Biomarker for Abdominal Aortic Aneurysms

Santiago Elizondo-Benedetto^{1*}, Sergio Sastriques-Dunlop^{1*}, Lisa Detering², Batool Arif¹, Gyu Seong Heo², Deborah Sultan², Hannah Luehmann², Xiaohui Zhang², Xuefeng Gao², Kitty Harrison², Dakkota Thies², Laura McDonald¹, Christophe Combadière³, Chieh-Yu Lin⁴, Yeona Kang⁵, Jie Zheng², Joseph Ippolito², Richard Laforest², Robert J. Gropler², Sean J. English¹, Mohamed A. Zayed^{1,2,6,7,8}, Yongjian Liu²

¹ Department of Surgery, Section of Vascular Surgery, ² Department of Radiology, ⁴ Department of Pathology and Immunology, ⁶ Division of Molecular Cell Biology, ⁷ Department of Biomedical Engineering; Washington University School of Medicine, St. Louis, MO, USA
³Sorbonne Université, INSERM, CNRS, Centre d'Immunologie et des Maladies Infectieuses, Cimi-Paris, F-75013 Paris, France

⁵ Department of Mathematics, Howard University, Washington D.C., USA

⁸ Veterans Affairs St. Louis Health Care System, St. Louis, MO, USA

*These authors contributed equally to this work.

This PDF file includes:

Supplemental Figures 1-7



Supplemental Figure 1. ⁶⁴Cu-DOTA-ECL1i PET/CT images in healthy volunteers (HVs) and patients with AAA. Yellow arrow: transverse view of infrarenal aortas in HVs. Green arrow: transverse view of AAAs.



Supplemental Figure 2. Distribution volume values for AAA patients and HV subjects. (A) Multiple image-derived input functions obtained from upper aorta. (B) Multiple image-derived input functions obtained from upper vena cava.



Supplemental Figure 3. Characterization of CCR2 expression in human aortic artery tissues. (**A**) Picture showing a human tissue of a healthy abdominal aortic artery (AA) stained with H&E and IF with CD68 and CCR2 specific antibodies. (**B**) Human sample of a non-ruptured abdominal aortic aneurysm (AAA) stained with H&E and IF with CD68 and CCR2 specific antibodies. (**C**) Human sample of a recently ruptured abdominal aortic aneurysm (RAAA) harvested during open surgical repair intervention, stained with H&E and IF with CD68 and CCR2 specific antibodies. (**D**) Representative picture of CD68+ and CCR2 + cells wall infiltration of RAAA human tissue respectively. (**E**) ⁶⁴Cu-DOTA-ECL1i autoradiography of RAAA tissue. Converted low-resolution images of IF staining of CCR2 (**F**) and autoradiography (**G**). The two sets of images were co-registered with representative regions-of-interest (ROIs, yellow squares). (**H**) Signals extracted from the ROIs of the two sets of images showed linear correlation.



Supplemental Figure 4. Assessment of CCR2 inhibition starting at day 0 on AAA progression and rupture in a MAAA rat model. (A) Comparison of AAA rupture rates between MAAA rats without treatment and those treated with CCR2i starting at day 0 (CCR2i D0). (B) Kaplan-Meier curve demonstrating significantly improved survival of MAAA rats following CCR2i D0 treatment. (C) Percent aortic diameter increase in MAAA vs CCR2i D0 groups at day 7 and day 14, respectively. Red dotted line is set at 100%. (D) Representative ⁶⁴Cu-DOTA-ECL1i PET/CT images at day 14 post PPE exposure showed specific and intense detection of AAA (yellow arrow) in MAAA, compared with the low trace accumulation in the CCR2i D0 treatment at day 7 and day 14 post PPE. Data presented as Mean \pm SD. *p < 0.05, **p < 0.01, ***p < 0.001, **** p<0.0001.



Supplemental Figure 5. Quantification of immunofluorescence intensity of CCR2+ cells and CD68+ macrophages within AAA wall following CCR2 inhibition in MAAA and FAAA models. (A) CCR2+ cells in non-treated MAAA vs CCR2i D3 (42±20 vs 16±5; respectively) in male rats. (B) CD68+ macrophages in non-treated MAAA vs CCR2i D3 (35 ± 19 , n=5 vs 21±10) in male rats. (C) CCR2+ cells in non-treated FAAA vs CCR2i D3 (30 ± 10 vs 13±9) in FAAA. (D) CD68+ macrophages in non-treated FAAA vs CCR2i D3 (37 ± 12 , n=7 vs 28±6) in FAAA. Data presented as Mean ± SD. *p < 0.05, **p < 0.01, ****p < 0.001, **** p<0.0001.



Supplemental Figure 6. Histopathological characterization of AAA in male and female rats following CCR2i. (A) Elastin degradation assessment in non-treated MAAA (n = 6 for severe) vs CCR2i in MAAA model (n= 3 for moderate and n = 2 for severe). (B) VSMC loss assessment in non-treated MAAA (n=6 severe) vs CCR2i (n=3 mild, n=1 moderate and n = 1 severe) in MAAA model. (C) Elastin degradation assessment in non-treated FAAA (n=1 mild, n= 1 moderate and n=2 for severe) vs CCR2i in FAAA model (n= 3 mild, n=4 moderate and n=1 severe). (D) VSMC loss assessment in non-treated FAAA (n=1 mild, n=1 severe). (D) VSMC loss assessment in non-treated FAAA (n=1 mild, n=2 severe) vs CCR2i in FAAA model (n=3 mild, n=1 moderate, n=2 severe) vs CCR2i in FAAA (n=3 mild, n=3 moderate and n=2 severe).



Supplemental Figure 7. Histopathological grading system for rat AAA tissue. (A) Table with grading system and measured parameters: Elastin degradation (mild = mostly intact elastin fibers with less than 10% of disruption; moderate = shredded elastin layers with 10-70% of disruption and severe more than 70% of elastin fiber disruption) and VSMC loss (mild = decreased nucleus density; moderate = 10-50% of decrease in nucleus density; and severe >50% decrease in nucleus density, VSMC mostly gone). VVG and H&E staining of abdominal aortas (cross-sectional) with 5x magnification and 10x magnification to visualize elastin degradation and VSMC loss in rats aortic tissue with either (B) mild (C) moderate and (D) severe example of analysis.